KYTHERA BIOPHARMACEUTICALS INC (KYTH) [Rocket]

In millions, except per share items	Jun-30-15	Mar-31-15	Dec-31-14	Sep-30-14	Jun-30-14	Mar-31-14	Dec-31-13	Sep-30-13
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Product sales, net	0.3		132.4				50.5
Product sales, net growth	-99.4%	162.3%	162.3%			184.2%	156.4%	-100.0%
Operating expenses:
Cost of sales	0.0
In-process research and development						52.8
Research and development	53.4	53.1	47.8	43.5	37.1	33.9	34.0	39.1
Selling, general and administrative	55.0	37.4	31.1	25.8	21.9	18.5	16.1	15.1
Total operating expenses	240.8	222.9	264.0	172.5	162.2	155.6	100.5	108.4
Loss from operations	-108.2	-90.6	-131.7	-122.1	-111.8	-105.2	-50.1	-54.3
Operating margin	100.0%	-68.4%	-99.4%	-241.8%	-221.4%	-208.4%	-99.2%
Interest income	0.3	0.2	0.3	0.2	0.2	0.2	0.1
Interest expense	-4.7	-4.6	-4.2	-3.5	-2.9	-2.2	-2.0	-1.7
Net loss	-112.7	-95.0	-135.6	-125.4	-114.5	-107.2	-51.9	-55.9

Other comprehensive income (loss):
Comprehensive loss	-112.8	-95.0	-135.7	-125.5	-114.4	-107.2	-51.9	-55.9

Per share information:
Net loss, basic and diluted (in dollars per share)	($4.74)	($4.16)	($6.10)	($5.69)	($5.32)	($5.13)	($2.72)	$3.68

Basic and diluted weighted average shares outstanding (in shares)	23.6	22.8	22.4	21.6	20.6	19.5	18.6	15.1